1. GSK allies with Innovax for COVID-19 vaccine R&D project— Zentalis Pharma raises $165M in IPO — Drug discovery in the age of coronavirus — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Libtayo expansion

Discussion in 'Regeneron' started by anonymous, Nov 21, 2019 at 11:49 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Who loves their new territory? Who believes 15 more reps will counteract a Keytruda indication successfully? Ha Ha. My territory got hacked.
     

  2. anonymous

    anonymous Guest

    This organization needs to exit oncology. This is another $%^& show like their previous attempt to enter the oncology arena. They are clueless and have no idea what they are doing. People have left and will continue to do so.
     
  3. anonymous

    anonymous Guest


    From the makers of ZalCRAP
     
  4. anonymous

    anonymous Guest

    And Praul-u-crap. Never made money, never will. Can’t give that crap away. Snake oil.
     
  5. anonymous

    anonymous Guest

    Going to be hard to fill the expansion roles if you have to keep backfilling the existing ones.
    At least staffing has some job security. :):rolleyes:
     
  6. anonymous

    anonymous Guest

    People are still interviewing like crazy and will as soon as they get back from the holidays. Let the resignations flow......
     
  7. anonymous

    anonymous Guest

    real answers
    Why do Sanofi and Libtayo management dislike each other? How do you expect the sales teams to produce results with our leaders acting like spoiled children in the sandbox fighting for the spotlight and credit?
     
  8. anonymous

    anonymous Guest

    As we all know...this is common with most pharma joint ventures. This will work itself out over time.
     
  9. anonymous

    anonymous Guest

    Insights into Oncology and management?
     
  10. anonymous

    anonymous Guest

    Well let's see.....

    Libtayo= $50million/qtr
    Keytruda=$3billion/qtr

    Keytruda will get CSCC indication by June but most likely before that date. When that happens, Libtayo will be toast. Merck knows a thing or two about contracts and their salesforce outnumbers ours. We're expanding but it will be way too late. They also have engaged many key academic centers in the keynote 630 trial which will get KOL's using Keytruda immediately.

    Management: Ahaaaaahaaaaahaaaaaaaaa.................they are clueless. This place is primary care. Growth goals are steep and unattainable for many.
     
  11. anonymous

    anonymous Guest

    So if I understand what you’re saying, Metoomavab’s days are numbered. So glad this asshat management team did not think I was the right fit.
     
  12. anonymous

    anonymous Guest

    This drug is a dog. Most the clinical trials discontinued since we were hired. It’s not the big we signed up for. Basal/cervical/lung all scrapped or years behind. At least the pay is average and we barely work at HQ, management and sales. Someday soon the gravy train will end when Pembro gets approved and we are all laid off or shuffled to another drug.
     
  13. anonymous

    anonymous Guest

    zalCRAP part II
     
  14. anonymous

    anonymous Guest

    There’s a foul odor coming from the oncology BU- smells like death.
     
  15. anonymous

    anonymous Guest

    The foul odor is probably blowing over from the Pralucrap team.
     
  16. anonymous

    anonymous Guest

    The stench from oncology BU is unbearable. Need to clean house and cleanup that mess. It’s only going to get worse with time.
     
  17. anonymous

    anonymous Guest

    Libtato is a bust. How long before “field staffers” get the boot?
     
  18. anonymous

    anonymous Guest

    Any lay offs coming in Oncology
     
  19. anonymous

    anonymous Guest

    Probably around Christmas 2020
     
  20. anonymous

    anonymous Guest


    What is “average” pay for sales?